Novartis's drug reduces heart failure deaths: study Reuters India ZURICH (Reuters) - Novartis's investigational medicine RLX030 reduced the number of deaths in patients with acute heart failure, the drugmaker said on Monday based on the results of a late-stage trial. RLX030 is form of the human hormone relaxin-2. Results from Novartis Phase III study show that RLX030 reduced deaths in ... Novartis: Phase III trial Shows RLX030 Reduces Deaths In Heart Failure Patients |
